Home > Integrated Solutions > New Targets and Biomarkers
New Targets and Biomarkers
By exploring thoroughly the patho-physiological map of a given disease, we help our clients identify new proteins than can become targets for the developing of new compounds.
Additionally, we help biopharma companies to elucidate the actual mechanism of action of drugs, which has to be explored from the network perspective.
The real MoA of drugs
Biomarkers Discovery
New developments in genomics, transcriptomics and metabolomics are increasing the amount of data available for analysis from the biomarkers perspective.
Altough a number of signals can be detected as increased / decreased expression levels of a pool of proteins, if we are not able to put those signals in biological context, their usefulness can be severely impaired.
A systems biology and protein network approach allows to put those signals into biological context, and allows to evaluate their real value as disease, diagnostic or pronostic biomarkers.
For example, Anaxomics solves questions like:
Are those signals relevant?- What new signals should be relevant, that we are currently missing?
- What combination of signals strenghtens the discrimination power?
- What is the mechanistic biological explanation of those signals to appear?
Anaxomics collaborates with companies specialized in proteomics, transcriptomics and metabolomics in order to offer the best rational approach to biomarkers discovery.
Please, contact us here to request more information.
